This week's View summarizes an article on the safety and efficacy outcomes of double vs. triple antithrombotic therapy in patients with atrial fibrillation and acute coronary syndrome who are treated with percutaneous coronary intervention, an article on the patient and health system-level factors associated with hospital readmission within 90 days after acute stroke or transient ischemic attack, and a trial that showed that an angiotensin receptor blocker was superior to placebo at slowing the rate of aortic root dilatation in patients with Marfan syndrome.

Subscribe on iTunes | Subscribe on Google Play

Keywords: EaglesEyeView, Acute Coronary Syndrome, Adrenergic beta-Antagonists, Angiotensin Receptor Antagonists, Anticoagulants, Aortic Diseases, Atrial Fibrillation, Blood Pressure, Blood Pressure Determination, Brain Ischemia, Cerebral Hemorrhage, Comorbidity, Dilatation, Fibrinolytic Agents, Heart Defects, Congenital, Hemorrhage, Intracranial Hemorrhages, Ischemic Attack, Transient, Losartan, Marfan Syndrome, Myocardial Infarction, Patient Discharge, Patient Readmission, Percutaneous Coronary Intervention, Primary Prevention, Rehabilitation, Secondary Prevention, Stents, Stroke, Thrombosis, Treatment Outcome, Vascular Diseases, Vitamin K, Warfarin, Vascular Diseases, Venous Thromboembolism, Arrhythmias, Cardiac, Cardiac Surgical Procedures

< Back to Listings